Development and testing of a polygenic risk score for breast cancer aggressiveness.

TitleDevelopment and testing of a polygenic risk score for breast cancer aggressiveness.
Publication TypeJournal Article
Year of Publication2023
AuthorsShieh, Y, Roger, J, Yau, C, Wolf, DM, Hirst, GL, Swigart, LBrown, Huntsman, S, Hu, D, Nierenberg, JL, Middha, P, Heise, RS, Shi, Y, Kachuri, L, Zhu, Q, Yao, S, Ambrosone, CB, Kwan, ML, Caan, BJ, Witte, JS, Kushi, LH, Veer, Lvan 't, Esserman, LJ, Ziv, E
JournalNPJ Precis Oncol
Volume7
Issue1
Pagination42
Date Published2023 May 15
ISSN2397-768X
Abstract

Aggressive breast cancers portend a poor prognosis, but current polygenic risk scores (PRSs) for breast cancer do not reliably predict aggressive cancers. Aggressiveness can be effectively recapitulated using tumor gene expression profiling. Thus, we sought to develop a PRS for the risk of recurrence score weighted on proliferation (ROR-P), an established prognostic signature. Using 2363 breast cancers with tumor gene expression data and single nucleotide polymorphism (SNP) genotypes, we examined the associations between ROR-P and known breast cancer susceptibility SNPs using linear regression models. We constructed PRSs based on varying p-value thresholds and selected the optimal PRS based on model r in 5-fold cross-validation. We then used Cox proportional hazards regression to test the ROR-P PRS's association with breast cancer-specific survival in two independent cohorts totaling 10,196 breast cancers and 785 events. In meta-analysis of these cohorts, higher ROR-P PRS was associated with worse survival, HR per SD = 1.13 (95% CI 1.06-1.21, p = 4.0 × 10). The ROR-P PRS had a similar magnitude of effect on survival as a comparator PRS for estrogen receptor (ER)-negative versus positive cancer risk (PRS) Furthermore, its effect was minimally attenuated when adjusted for PRS, suggesting that the ROR-P PRS provides additional prognostic information beyond ER status. In summary, we used integrated analysis of germline SNP and tumor gene expression data to construct a PRS associated with aggressive tumor biology and worse survival. These findings could potentially enhance risk stratification for breast cancer screening and prevention.

DOI10.1038/s41698-023-00382-z
Alternate JournalNPJ Precis Oncol
PubMed ID37188791
PubMed Central IDPMC10185660
Grant ListU01 CA195565 / CA / NCI NIH HHS / United States
K08 CA237829 / CA / NCI NIH HHS / United States
R01 CA129059 / CA / NCI NIH HHS / United States
R01 CA105274 / CA / NCI NIH HHS / United States
K24 CA169004 / CA / NCI NIH HHS / United States
P01 CA210961 / CA / NCI NIH HHS / United States
U01 CA196406 / CA / NCI NIH HHS / United States